<p>The present invention relates to transgenic pigs containing a dominant-negative incretin hormone receptor, namely the dominant-negative human glucose-dependent insulinotropic polypeptide receptor. The present invention furthermore relates to uses of these transgenic pigs as clinically relevant animal model systems for studying the development and novel therapies for diabetes mellitus type 2, particularly for the maintenance and expansion of pancreatic ²-cell mass.</p>
